GSK Stock Forecast for 2023 - 2025 - 2030
Updated on 05/19/2024
GSK Stock Forecast and Price Target
The average price target of £19.95 for GSK's stock set by twelve distinguished analysts in recent weeks would represent a potential upside of approximately 12.39% from the last closing price in May, 2024 if reached by the end of the year. This potential increase is based on a high estimate of £34.79 and a low estimate of £12.00. If you are not interested in GSK stock, you may be interested in its competitors.
12.39% Upside
GSK Fair Value Forecast for 2023 - 2025 - 2030
GSK's Price has decreased In the last four years, from £17.24 to £0.00 – a 100.00% drop. In the next year, analysts believe that Fair Value will reach £18.55 – an increase of 100.00%. For the next seven years, the forecast is for Fair Value to grow by 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| ABBV Stock Forecast | AbbVie | Outperform |
9
|
$166.42 | Buy/Sell | $178.42 | 9.66% |
| AZN Stock Forecast | AstraZeneca PLC | Outperform |
17
|
£121.10 | Buy/Sell | £165.99 | 34.64% |
| ABT Stock Forecast | Abbott Laboratories | Outperform |
9
|
$104.09 | Buy/Sell | $118.92 | 21.53% |
| AMGN Stock Forecast | Amgen | Outperform |
4
|
$312.47 | Buy/Sell | $303.65 | 2.41% |
| CSL Stock Forecast | CSL | Outperform |
12
|
$280.00 | Buy/Sell | $205.51 | -26.66% |
GSK Revenue Forecast for 2023 - 2025 - 2030
GSK's Revenue has decreased In the last three years, from £34.10B to £30.33B – a 11.06% drop. In the next year, analysts believe that Revenue will reach £31.19B – an increase of 2.84%. For the next seven years, the forecast is for Revenue to grow by 13.19%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| BMY Stock Forecast | Bristol-Myers Squibb | Hold |
2
|
$44.03 | Buy/Sell | $58.15 | 22.64% |
| GILD Stock Forecast | Gilead Sciences Inc | Outperform |
11
|
$67.72 | Buy/Sell | $87.82 | 18.13% |
| CL Stock Forecast | Colgate-Palmolive Co | Outperform |
18
|
$94.13 | Buy/Sell | $88.97 | 4.64% |
.jpg)
GSK Dividend per Share Forecast for 2023 - 2025 - 2030
In the last three years, GSK's Dividend per Share has seen a drop from £1.00 to £0.58 – a 42.00% decrease. In the next year, analysts believe that Dividend per Share will reach £0.61 – an increase of 5.17%. For the next seven years, experts predict that GSK's Dividend per Share will grow at a rate of 22.41%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| BDX Stock Forecast | Becton Dickinson and Co | Outperform |
9
|
$236.30 | Buy/Sell | $284.47 | 17.44% |
| 4568 Stock Forecast | Daiichi Sankyo Company | Buy |
4
|
¥5.53k | Buy/Sell | ¥5.24k | 7.58% |
| MMM Stock Forecast | 3M | Hold |
10
|
$105.26 | Buy/Sell | $109.39 | -1.67% |
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| 4519 Stock Forecast | Chugai Pharmaceutical | Outperform |
6
|
¥5.01k | Buy/Sell | ¥4.92k | 21.83% |
| A Stock Forecast | Agilent Technologies | Outperform |
10
|
$154.23 | Buy/Sell | $138.82 | -2.09% |
| ALC Stock Forecast | Alcon | Outperform |
8
|
CHF80.08 | Buy/Sell | CHF90.64 | 20.97% |
GSK EBITDA Forecast for 2023 - 2025 - 2030
In the last three years, GSK's EBITDA has fallen from £10.32B to £10.30B – a 0.16% decrease. For the next year, analysts predict that EBITDA will reach £10.62B – an increase of 3.08%. Over the next seven years, experts believe that GSK's EBITDA will grow at a rate of 46.82%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| BN Stock Forecast | Danone | Outperform |
11
|
59.94€ | Buy/Sell | 55.47€ | 6.77% |
| CTVA Stock Forecast | Corteva | Outperform |
12
|
$56.45 | Buy/Sell | $61.72 | 15.15% |
| ABEV3 Stock Forecast | Ambev | Outperform |
10
|
R$12.38 | Buy/Sell | R$15.65 | 27.22% |
GSK EBIT Forecast for 2023 - 2025 - 2030
In the last three years, GSK's EBIT has decreased from £8.44B to £8.40B – a 0.38% drop. In the next year, analysts predict that EBIT will jump to £9.15B – up 8.84% from the current level. Looking ahead to seven years, experts forecast that EBIT will grow by 17.56%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| HEN3 Stock Forecast | Henkel AG & Co. KGaA | Hold |
16
|
83.98€ | Buy/Sell | 71.63€ | -3.55% |
| BEI Stock Forecast | Beiersdorf | Outperform |
17
|
144.70€ | Buy/Sell | 137.41€ | 2.97% |
| BAYN Stock Forecast | Bayer | Hold |
5
|
28.58€ | Buy/Sell | 45.15€ | 4.97% |
GSK EPS Price Prediction Forecast for 2023 - 2025 - 2030
GSK's EPS has decreased In the last four years, from £1.45 to £0.00 – a 100.00% drop. In the next year, analysts believe that EPS will reach £1.56 – an increase of 100.00%. For the next seven years, the forecast is for EPS to grow by 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| ADM Stock Forecast | Archer-Daniels-Midland | Hold |
8
|
$61.62 | Buy/Sell | $67.70 | 2.24% |
| COLO B Stock Forecast | Coloplast A/S | Hold |
18
|
kr850.00 | Buy/Sell | kr812.28 | 5.88% |
| CHD Stock Forecast | Church & Dwight Co Inc | Hold |
11
|
$106.39 | Buy/Sell | $96.90 | 1.51% |
.jpg)